Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: An optimal delivery of siRNA and anticancer drug

Clinical Cancer Research

Volumn 19, Issue 22, 2013, Pages 6193-6204

  Shah, Vatsal ^a   Taratula, Oleh ^a,c   Garbuzenko, Olga B ^a   Taratula, Olena R ^c   Rodriguez Rodriguez, Lorna ^b   Minko, Tamara ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HERMES ANTIGEN; LUTEINIZING HORMONE RELEASING HORMONE POLYPROPYLENIMINE DENDRIMER PACLITAXEL CONJUGATE; LUTEINIZING HORMONE RELEASING HORMONE POLYPROPYLENIMINE DENDRIMER SMALL INTERFERING RNA CONJUGATE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; SUCCINIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CD44 GENE; CELL ISOLATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MDR1 GENE; MOUSE; NANOPHARMACEUTICS; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; OVARY METASTASIS; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ASCITIC FLUID; BIOLOGICAL TRANSPORT; DENDRIMERS; FEMALE; GENE EXPRESSION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MICE; MICE, NUDE; NANOMEDICINE; NANOPARTICLES; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PILOT PROJECTS; POLYPROPYLENES; RECEPTORS, LHRH; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 84888089856     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1536     Document Type: Article

References (41)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
3. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997;71:241-319. (Pubitemid 27197761)
4. Bajorath J, Greenfield B, Munro SB, Day AJ, Aruffo A. Identification of CD44 residues important for hyaluronan binding and delineation of the binding site. J Biol Chem 1998;273:338-43. (Pubitemid 28042214)
5. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A 1992;89:12160-4. (Pubitemid 23004805)
6. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990;61:1303-13.
7. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008;283:17635-51.
8. Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Gunthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994;124:71-82. (Pubitemid 24054611)
9. Rodriguez-Rodriguez L, Sancho-Torres I, Leakey P, Gibbon DG, Comerci JT, Ludlow JW, et al. CD44 splice variant expression in clear cell carcinoma of the ovary. Gynecol Oncol 1998;71:223-9. (Pubitemid 28550805)
10. Rodriguez-Rodriguez L, Sancho-Torres I, Mesonero C, Gibbon DG, Shih WJ, Zotalis G. The CD44 receptor is a molecular predictor of survival in ovarian cancer. Med Oncol 2003;20:255-63. (Pubitemid 37193937)
11. Speiser P, Wanner C, Breitenecker G, Kohlberger P, Kainz C. CD-44 is not involved in the metastatic spread of ovarian cancer in vivo. Anticancer Res 1995;15:2767-9. (Pubitemid 26095096)
12. Stadlmann S, Raffeiner R, Amberger A, Margreiter R, Zeimet AG, Abendstein B, et al. Disruption of the integrity of human peritoneal mesothelium by interleukin-1beta and tumor necrosis factor-alpha. Virchows Arch 2003;443:678-85. (Pubitemid 37500149)
13. Chiu YL, Ali A, Chu CY, Cao H, Rana TM. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 2004;11:1165-75. (Pubitemid 39138769)
14. de Fougerolles A, Vornlocher H-P, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007;6:443-53. (Pubitemid 47064567)
15. Song E, Zhu PC, Lee S-K, Chowdhury D, Kussman S, Dykxhoorn DM, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotech 2005;23:709-17. (Pubitemid 41716361)
16. Uprichard SL. The therapeutic potential of RNA interference. FEBS Lett 2005;579:5996-6007. (Pubitemid 41484145)
17. Betigeri S, Pakunlu RI, Wang Y, Khandare JJ, Minko T. JNK1 as a molecular target to limit cellular mortality under hypoxia. Mol Pharm 2006;3:424-30. (Pubitemid 44351925)
18. Patil ML, Zhang M, Betigeri S, Taratula O, He H, Minko T. Surfacemodified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug Chem 2008;19:1396-403. (Pubitemid 352032339)
19. Patil ML, Zhang M, Minko T. Multifunctional triblock Nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing. ACS Nano 2011;5:1877-87.
20. Patil ML, Zhang M, Taratula O, Garbuzenko OB, He H, Minko T. Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. Biomacromolecules 2009;10:258-66.
21. Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine 2008;3:761-76.
22. Taratula O, Garbuzenko O, Savla R, Wang YA, He H, Minko T. Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. Curr Drug Deliv 2011;8:59-69.
23. Taratula O, Garbuzenko OB, Chen AM, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target 2011;19:900-14.
24. Taratula O, Garbuzenko OB, Kirkpatrick P, Pandya I, Savla R, Pozharov VP, et al. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release 2009;140:284-93.
25. Taratula O, Savla R, He H, Minko T. Poly (propyleneimine) dendrimers as potential siRNA delivery nanocarrier: from structure to function. Int J Nanotechnol 2011;8:36-52.
26. Zinselmeyer BH, Mackay SP, Schatzlein AG, Uchegbu IF. The lowergeneration polypropylenimine dendrimers are effective gene-transfer agents. Pharm Res 2002;19:960-7. (Pubitemid 34808705)
27. Jayant S, Khandare JJ, Wang Y, Singh AP, Vorsa N, Minko T. Targeted sialic acid-doxorubicin prodrugs for intracellular delivery and cancer treatment. Pharm Res 2007;24:2120-30. (Pubitemid 47493581)
28. Pakunlu RI, Wang Y, Tsao W, Pozharov V, Cook TJ, Minko T. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res 2004;64:6214-24. (Pubitemid 39129423)
29. Shah V, Taratula O, Garbuzenko OB, Patil ML, Savla R, Zhang M, et al. Genotoxicity of different nanocarriers: possible modifications for the delivery of nucleic acids. Curr Drug Discov Technol 2013;10:8-15.
30. Chandna P, Khandare JJ, Ber E, Rodriguez-Rodriguez L, Minko T. Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers. Pharm Res 2010;27:2296-306.
31. Chandna P, Saad M, Wang Y, Ber E, Khandare J, Vetcher AA, et al. Targeted proapoptotic anticancer drug delivery system. Mol Pharm 2007;4:668-78. (Pubitemid 350004266)
32. Zhang M, Garbuzenko OB, Reuhl KR, Rodriguez-Rodriguez L, Minko T. Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. Nanomedicine 2012;7:185-97.
33. Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S, et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A 2005;102:12962-7. (Pubitemid 41279472)
34. Betigeri S, Zhang M, Garbuzenko O, Minko T. Non-viral systemic delivery of siRNA or antisense oligonucleotides targeted to Jun. N-terminal kinase 1 prevents cellular hypoxic damage. Drug Deliv Transl Res 2011;1:13-24.
35. Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci U S A 2010;107:10737-42.
36. Garbuzenko OB, Saad M, Betigeri S, Zhang M, Vetcher AA, Soldatenkov VA, et al. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm Res 2009;26:382-94.
37. Saad M, Garbuzenko OB, Ber E, Chandna P, Khandare JJ, Pozharov VP, et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release 2008;130:107-14.
38. Miletti-Gonzalez KE, Chen S, Muthukumaran N, Saglimbeni GN, Wu X, Yang J, et al. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 2005;65:6660-7. (Pubitemid 41060702)
39. Dharap SS, Minko T. Targeted proapoptotic LHRH-BH3 peptide. Pharm Res 2003;20:889-96. (Pubitemid 36628435)
40. Khandare JJ, Jayant S, Singh A, Chandna P, Wang Y, Vorsa N, et al. Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconjug Chem 2006;17:1464-72. (Pubitemid 44851491)
41. Benjaminsen RV, Mattebjerg MA, Henriksen JR, Moghimi SM, Andresen TL. The possible "proton sponge" effect of polyethylenimine (PEI) does not include change in lysosomal pH. Mol Ther 2013;21:149-57.